Assessment of tumor tissue oxygenation: Agents, methods and clinical significance

Drug News and Perspectives

Volumn 20, Issue 10, 2007, Pages 619-626

  Pauwels, Ernest K J ^a,b   Mariani, Giuliano ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ANTIBODY; ANTIBODY M75; BENZENESULFONAMIDE DERIVATIVE; BMS 191321; BMS 194796; BSM 181321; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; CONTRAST MEDIUM; COPPER 64; DIACETYLBIS N4 METHYLTHIOSEMICARBAZONE; FLUORINE 18; FLUOROAZOMYCIN ARABINOSIDE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; MOLYBDENUM 99; NITROIMIDAZOLE DERIVATIVE; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; TECHNETIUM 99M; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; CANCER INHIBITION; CANCER THERAPY; CANCER TISSUE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HYPOXIA; HYPOXIC CELL; IMMUNOHISTOCHEMISTRY; INVASIVE PROCEDURE; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN ELECTRODE; PATHOPHYSIOLOGY; PATIENT SELECTION; PHYSICIAN; POLAROGRAPHY; PROGNOSIS; PROTEIN DEGRADATION; RESEARCH; REVIEW; SCINTIGRAPHY; SOLID TUMOR; THERAPY EFFECT; TISSUE OXYGENATION; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR GROWTH;

CELL HYPOXIA; ELECTRODES; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POLAROGRAPHY; PROGNOSIS; RADIONUCLIDE IMAGING;

EID: 41149108071     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2007.20.10.1181355     Document Type: Review

References (46)

1. Vaupel, P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004, 9(Suppl. 5): 10-7.
2. Boyle, R.G. and Travers, S. Hypoxia: Targeting the tumour. Anticancer Agents Med Chem 2006, 6(4): 281-6.
3. Rak, J., Yu, J.L., Kerbel, R.S. and Coomber, B.L. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res 2002, 62(7): 1931-4.
4. Kerbel, R. and Folkman, J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2(10): 727-39.
5. Rak, J., Milsom, C., May, L., Klement, P. and Yu, J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006, 32(1): 54-70.
6. Zhou, J., Schmid, T., Schnitzer, S. and Brune, B. Tumor hypoxia and cancer progression. Cancer Lett 2006, 237(1): 10-21.
7. Vogelstein, B. and Kinzler, K.W. Cancer genes and the pathways they control. Nat Med 2004, 10(8): 789-99.
8. Patiar S. and Harris, A.L. Role of hypoxia-inducible factor-1 alpha as a cancer therapy target. Endocr Relat Cancer 2006, 13(Suppl. 1): S61-75.
9. Tatum, J.L., Kelloff, G.J., Gillies, R.J. et al. Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006, 82(10): 699-757.
10. Milosevic, M., Fyles, A., Hedley, D. and Hill, R. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 2004, 14(3): 249-58.
11. Vaupel, P. and Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26(2): 225-39.
12. Airley, R.E. and Mobasheri, A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007, 53(4): 233-56.
13. Talks, K.L., Turley, H., Gatter, K.C., Maxwel,l .P.H, Pugh, C.W., Ratcliffe, P.J. and Harris, A.L. The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000, 157(2): 411-21.
14. Soilleux, E.J., Turley, H., Tian, Y.M., Pugh, C.W., Gatter, K.C. and Harris, A.L. Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues. Histopathology 2005, 47(6): 602-10.
15. Bachtiary, B., Schindl, M., Pötter, R. et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003, 9(6): 2234-40.
16. Mayer, A., Hockel, M. and Vaupel, P. Endogenous hypoxia markers in locally advanced cancers of the uterine cervix: reality or wishful thinking? Strahlenther Onkol 2006, 182(9): 501-10.
17. Vordermark, D. and Brown, J.M. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol 2003, 179(12): 801-11.
18. Haider, M.A., Milosevic, M., Fyles, A. et al. Assessment of the tumor microenvironment in cervix cancer using dynamic contrast enhanced CT, interstitial fluid pressure and oxygen measurements. Int J Radiat Oncol Biol Phys 2005, 62(4): 1100-7.
19. Gagel, B., Piroth, M., Pinkawa, M. et al. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer 2007, 7: 113.
20. Morgan, V.L., and Price, R.R. The effect of sensorimotor activation on functional connectivity mapping with MRI. Magn Reson Imaging 2004, 22(8): 1069-75.
21. Howe, F.A., Robinson, S.P., McIntyre, D.J., Stubbs, M. and Griffiths, J.R. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 2001, 14(7-8): 497-506.
22. Bourke, V.A., Zhao, D., Gilio, J., Chang, C.H., Jiang, L., Hahn, E.W. and Mason, R.P. Correlation of radiation response with tumor oxygenation in the Dunning prostate R3327-AT1 tumor. Int J Radiat Oncol Biol Phys 2007, 67(4): 1179-86.
23. Adams, G.E. and Stratford, I.J. Hypoxia-mediated nitro-heterocyclic drugs in the radio- and chemotherapy of cancer. An overview. Biochem Pharmacol 1986, 35(1): 71-6.
24. Melo, T., Hua, H.A., Ballinger, J.R. and Rauth, A.M. Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazole, with unlabelled nitroaromatics. Biochem Pharmacol 1997, 54(6): 685-93.
25. Melo, T., Tunggal, J.K., Ballinger, J.R. and Rauth, A.M. Flux through multicellular layers of a technetium-99m-nitroimidazole for imaging hypoxia. Cancer Biother Radiopharm 2002, 17(5): 515-26.
26. Kumar, P., Wiebe, L.I., Mannan, R.H., Zhang Z., Xia, H. and McEwan, A.J. 99mTc-Technetium labelled PnAo-azomycin glucuronides: a novel class of imaging markers of tissue hypoxia. Appl Radiat Isot 2002, 57(5): 719-28.
27. Mallia, M.B., Subramanian, S., Banerjee, S., Sarma, H.D., Venkatesh, M. Evaluation of 99mTc(CO)3 complex of 2-methyl-5-nitroimidazole as an agent for targeting tumor hypoxia. Bioorg Med Chem 2006, 14(23): 7666-70.
28. Eschmann, S.M., Paulsen, F., Bedeshem, C., Machulla, H.J., Hehr, T., Bamberg, M. and Bares, R. Hypoxia-imaging with (18)F-Misonidazole and PET: Changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol 2007, 83(3): 406-10.
29. Gagel, B., Reinartz, P., Demirel, C. e al. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 2006, 6: 51.
30. Krause, B.J., Beck, R., Souvatzoglou, M. and Piert, M. PET and PET/CT studies of tumor tissue oxygenation. Q J Nucl Med Mol Imaging 2006, 50(1): 28-43.
31. Souvatzoglou, M., Grosu, A.L., Roper, B. et al. Tumour hypoxia imaging with [(18)F]FATA PET in head and neck cancer patients: A pilot study. Eur J Nucl Med Mol Imaging. 2007 Apr 20; [Epub ahead of print].
32. Matsumoto, K., Szajek, L., Krishna, M.C. et al. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography. Int J Oncol 2007, 30(4): 873-81.
33. Grigsby, P.W., Malyapa, R.S., Higashikubo, R., Schwarz, J.K., Welch, M.J., Huettner, P.C. and Dehdashti, F. Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix. Mol Imaging Biol 2007, 9(5): 278-83.
34. Dehdashti, F., Mintun, M.A., Lewis, J.S. et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003, 30(6): 844-50.
35. Yuan, H., Schroeder, T., Bowsher, J.E., Hedlund, L.W., Wong, T. and Dewhirst, M.W. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003, 30(6): 844-50.
36. Williams, K.J., Parker, C.A. and Stratford, I.J. Exogenous and endogenous markers of tumour oxygenation status: definitive markers of tumour hypoxia? Adv Exp Med Biol 2005, 566: 285-94.
37. Pastorekova, S., Parkkila, S. and Zavada, J. Tumor-associated carbonic anhydrases and their clinical significance. Adv Clin Chem 2006, 42: 167-216.
38. Said, H.M., Hagemann, C., Staab, A. et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol 2007, 83(3): 398-405.
39. Zat'ovicova, M., Tarabkova, K., Svastova, E. et al. Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX. J Immunol Methods 2003, 282(1-2): 117-34.
40. Hendrickx, B.W., Punt, C.J., Boerman, O.C. et l. Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250. Cancer Biother Radiopharm 2006, 21(3): 263-8.
41. Brouwers, A.H., Mulders, P.F., de Mulder, P.H. et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol 2005, 23(27): 6540-8.
42. Chrastina, A., Zavada, J., Parkkila, S. et al. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer 2003, 105(6): 873-81.
43. Cecchi, A., Taylor, S.D., Liu, Y., Hill, B., Vullo, D., Scozzafava, A. and Supuran, C.T. Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett 2005, 15(23): 5192-6.
44. Salmon, A.J., Williams, M.L., Innocenti, A., Vullo, D., Supuran, C.T. and Poulsen, S.A. Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety. Bioorg Med Chem Lett 2007, [Epub ahead of print].
45. Wilkinson, B.L., Bornaghi, L.F., Houston, T.A., Innocenti, A., Vullo, D., Supuran, C.T. and Poulsen, S.A. Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides. J Med Chem. 2007, 50(7): 1651-7.
46. Pastorekova, S., Kopacek, J. and Pastorek, J. Carbonic anhydrase inhibitors and the management of cancer. Curr Top Med Chem 2007, 7(9): 865-78.